Evoke Pharma (NASDAQ:EVOK) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Friday. The firm currently has a $2.75 price objective on the specialty pharmaceutical company’s stock. Zacks Investment Research‘s price objective points to a potential upside of 12.70% from the stock’s current price.

According to Zacks, “Evoke Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. The Company’s lead product candidate, EVK-001, is in late stage clinical testing which is intended for the treatment of diabetic gastroparesis. Evoke Pharma, Inc. is based in San Diego, California. “

Several other equities analysts have also issued reports on EVOK. HC Wainwright set a $9.00 price target on Evoke Pharma and gave the company a “buy” rating in a research note on Friday. ValuEngine lowered Evoke Pharma from a “hold” rating to a “sell” rating in a research note on Monday, July 2nd. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $7.79.

Evoke Pharma stock traded up $0.08 during mid-day trading on Friday, reaching $2.44. 56,399 shares of the company were exchanged, compared to its average volume of 83,661. Evoke Pharma has a 12 month low of $1.85 and a 12 month high of $4.09. The firm has a market cap of $42.58 million, a PE ratio of -2.94 and a beta of 1.46.

Evoke Pharma (NASDAQ:EVOK) last posted its quarterly earnings data on Thursday, August 9th. The specialty pharmaceutical company reported ($0.14) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.16) by $0.02. equities analysts expect that Evoke Pharma will post -0.52 earnings per share for the current year.

An institutional investor recently bought a new position in Evoke Pharma stock. Deutsche Bank AG purchased a new stake in Evoke Pharma Inc (NASDAQ:EVOK) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 200,000 shares of the specialty pharmaceutical company’s stock, valued at approximately $452,000. Deutsche Bank AG owned about 1.30% of Evoke Pharma as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 13.75% of the company’s stock.

Evoke Pharma Company Profile

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray, which is in Phase 2b clinical trials for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.

Further Reading: Momentum Indicator: Relative Strength Index

Get a free copy of the Zacks research report on Evoke Pharma (EVOK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Evoke Pharma (NASDAQ:EVOK)

Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.